MX2016015346A - Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. - Google Patents

Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Info

Publication number
MX2016015346A
MX2016015346A MX2016015346A MX2016015346A MX2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A
Authority
MX
Mexico
Prior art keywords
death
radiotherapy
combination
cancer treatment
treatment methods
Prior art date
Application number
MX2016015346A
Other languages
English (en)
Other versions
MX382472B (es
Inventor
Morrow Michelle
Stewart Ross
DOVEDI Simon
Illidge Tim
Wilkinson Robert
Poon Edmund
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53498965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016015346A publication Critical patent/MX2016015346A/es
Publication of MX382472B publication Critical patent/MX382472B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud proporciona un método para tratar cáncer en un paciente que comprende administrar al menos una dosis de radioterapia y al menos un antagonista de PD-1 y/o PD-L1, en el que al menos un antagonista de PD-1 y/o PD-L1 se administra el mismo día que una dosis de radioterapia o hasta e incluyendo 4 días después.
MX2016015346A 2014-06-17 2015-06-17 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinación con radioterapia. MX382472B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013157P 2014-06-17 2014-06-17
PCT/EP2015/063552 WO2015193352A1 (en) 2014-06-17 2015-06-17 Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Publications (2)

Publication Number Publication Date
MX2016015346A true MX2016015346A (es) 2017-08-10
MX382472B MX382472B (es) 2025-03-13

Family

ID=53498965

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016015346A MX382472B (es) 2014-06-17 2015-06-17 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinación con radioterapia.
MX2021004821A MX2021004821A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021004828A MX2021004828A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021004821A MX2021004821A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021004828A MX2021004828A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Country Status (19)

Country Link
US (2) US10092645B2 (es)
EP (2) EP3157629B1 (es)
JP (5) JP6877147B2 (es)
KR (4) KR20230113847A (es)
CN (1) CN107073107A (es)
AU (3) AU2015276173B2 (es)
BR (1) BR112016028964A2 (es)
CA (1) CA2950046C (es)
DK (1) DK3157629T3 (es)
ES (1) ES2933603T3 (es)
HU (1) HUE060689T2 (es)
IL (1) IL249133B (es)
MX (3) MX382472B (es)
PL (1) PL3157629T3 (es)
PT (1) PT3157629T (es)
RU (1) RU2711408C2 (es)
SG (2) SG10202108654PA (es)
TW (2) TWI781021B (es)
WO (1) WO2015193352A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3043816T3 (pl) * 2013-09-11 2020-03-31 Medimmune Limited Przeciwciała anty-b7-h1 do leczenia nowotworów
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3212228B1 (en) * 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
MA44146B1 (fr) 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
IL260937B2 (en) * 2016-02-06 2024-07-01 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
EP3532494A4 (en) * 2016-10-26 2020-06-03 The Children's Medical Center Corporation METHOD AND COMPOSITIONS FOR MODULATING TRANSFORMATION GROWTH FACTOR BETA-REGULATED FUNCTIONS
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
IL321717A (en) 2017-02-21 2025-08-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019094265A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Pd1 polypeptide binding molecules
JP7312168B2 (ja) * 2017-11-13 2023-07-20 クレッシェンド、バイオロジックス、リミテッド Ｃｄ１３７に結合するシングルドメイン抗体
CN120173101A (zh) 2018-03-22 2025-06-20 表面肿瘤学有限责任公司 抗il-27抗体及其用途
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
US10949272B2 (en) * 2018-06-14 2021-03-16 Microsoft Technology Licensing, Llc Inter-application context seeding
EP3880186B1 (en) 2018-11-14 2024-04-03 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
BR112021010799A2 (pt) 2018-12-03 2021-08-24 Fusion Pharmaceuticals Inc. Terapia combinada com radioimunoconjugados e inibidor do ponto de verificação
KR102167539B1 (ko) * 2018-12-28 2020-10-20 한국원자력의학원 방사선 치료 시 변화되는 암 세포의 면역관문인자 발현수준을 측정하는 단계를 포함하는 방사선 치료 예후 예측을 위한 정보제공방법 및 방사선 치료 병용 암 치료용 조성물
KR102195221B1 (ko) * 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
WO2021231528A1 (en) * 2020-05-12 2021-11-18 Rush University Medical Center Compositions and methods for treating cancer
CN115340602B (zh) * 2020-08-19 2024-07-30 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN116490244A (zh) * 2020-11-18 2023-07-25 武田药品工业株式会社 Sting激动剂、检查点抑制剂和辐射的施用
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CN102935228B (zh) * 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
KR101981873B1 (ko) * 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
SG10201704992SA (en) 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20160002731A1 (en) * 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US20150344577A1 (en) 2013-01-11 2015-12-03 Dingfu Biotarget Co., Ltd Agents for treating tumors, use and method thereof
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Also Published As

Publication number Publication date
EP3157629B1 (en) 2022-10-05
IL249133B (en) 2022-04-01
KR20220082097A (ko) 2022-06-16
TW201617093A (zh) 2016-05-16
SG10202108654PA (en) 2021-09-29
AU2015276173B2 (en) 2020-08-20
US20190192655A1 (en) 2019-06-27
KR102592781B1 (ko) 2023-10-20
EP4144412A1 (en) 2023-03-08
ES2933603T3 (es) 2023-02-10
CA2950046A1 (en) 2015-12-23
KR20230113847A (ko) 2023-08-01
BR112016028964A2 (pt) 2017-10-17
PT3157629T (pt) 2022-12-20
TWI751101B (zh) 2022-01-01
HUE060689T2 (hu) 2023-04-28
RU2711408C2 (ru) 2020-01-17
SG11201610600SA (en) 2017-01-27
CA2950046C (en) 2023-02-14
JP6877147B2 (ja) 2021-05-26
EP3157629A1 (en) 2017-04-26
JP2023093538A (ja) 2023-07-04
DK3157629T3 (da) 2022-12-19
MX2021004821A (es) 2021-08-19
IL249133A0 (en) 2017-01-31
TW202228777A (zh) 2022-08-01
RU2017101312A3 (es) 2019-01-29
KR20170015460A (ko) 2017-02-08
MX382472B (es) 2025-03-13
PL3157629T3 (pl) 2023-01-30
JP2022031638A (ja) 2022-02-22
MX2021004828A (es) 2021-09-21
US10092645B2 (en) 2018-10-09
AU2023202654A1 (en) 2023-05-18
JP2017525661A (ja) 2017-09-07
WO2015193352A1 (en) 2015-12-23
TWI781021B (zh) 2022-10-11
AU2023202654B2 (en) 2025-12-18
JP2020121978A (ja) 2020-08-13
JP2025028053A (ja) 2025-02-28
AU2020210207B2 (en) 2023-02-02
AU2020210207A1 (en) 2020-08-20
JP7258981B2 (ja) 2023-04-17
AU2015276173A1 (en) 2016-12-22
RU2017101312A (ru) 2018-07-20
CN107073107A (zh) 2017-08-18
KR20240162170A (ko) 2024-11-14
US20160051672A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
MX2016015346A (es) Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EP4461298A3 (en) Methods of treatment with cyp3a4 substrate drugs
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2019013862A (es) Terapia de combinacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
MY189663A (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2020001727A (es) Terapia de combinacion.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX380835B (es) Terapia de combinación pac-1.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP2786764A3 (en) Combination therapy using anti-c-met antibody and sorafenib
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.